Brain Cancer clinical trials in Nebraska

10 actively recruiting brain cancer trials at 3 sites across Nebraska.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology

NCT ID: NCT06500455

Sites in Nebraska:

Nebraska Medicine-Bellevue — Bellevue, Nebraska
Nebraska Medicine-Village Pointe — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04166409

Sites in Nebraska:

Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals

NCT ID: NCT05580562

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.

NCT ID: NCT05566795

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT04511013

Sites in Nebraska:

Cancer Partners of Nebraska - Pine Lake — Lincoln, Nebraska
Southeast Nebraska Cancer Center - 68th Street Place — Lincoln, Nebraska

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05099003

Sites in Nebraska:

Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.

Sponsor: University of Nebraska

NCT ID: NCT04222062

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

A Study Utilizing Escitalopram in Glioma Patients

Glioma is a cancer of glial cells, a class of tissue supporting neuronal function in the brain. As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also from therapy such a…

Sponsor: University of Nebraska

NCT ID: NCT03728673

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Nebraska:

Massive Bio SYNERGY-AI site — Omaha, Nebraska

View on ClinicalTrials.gov →

Recruiting Academic/Other

Assessment of Eloquent Function in Brain Tumor Patients

Purpose of the study: AIM 1: Prospectively collect pre-operative \[functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), magnetoencephalography (MEG)\] and intra-operative mapping data in patients with intra-axial b…

Sponsor: University of Nebraska

NCT ID: NCT01535430

Sites in Nebraska:

University of Nebraska Medical Center — Omaha, Nebraska

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20